Filing
4th Quarter - Report
Lobbying activity
1
Advocating to remove non-payer discounts from the ASP calculation for Medicare Part B Promoting a resilient pharmaceutical supply chain Advocating to amend Hatch-Waxman to limit brand companies from serially suing generic companies over the same molecule. issues related to generic and biosimilar access